IL-17 BINDING PROTEINS
First Claim
Patent Images
1. A binding protein comprising an antigen binding domain capable of binding human IL-17, said antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of:
- CDR-H1. X1-X2-X3-X4-X5 (SEQ ID NO;
919), wherein;
X1 is D or S;
X2 is Y;
X3 is E or G;
X4 is I, M, V, or F;
X5 is H;
CDR-H2. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17 (SEQ ID NO;
920), wherein;
X1 is V;
X2 is T, I, or N;
X3 is D, H, or W;
X4 is P or is not present;
X5 is E, G, or S;
X6 is S, N, or D;
X7 is G;
X8 is G or T;
X9 is T;
X10 is L, A, T, or F;
X11 is H or Y;
X12 is N;
X13 is P, Q, or S;
X14 is K, A, or N;
X15 is F or L;
X16 is D, K, or R; and
X17 is G, D, or S;
CDR-H3. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 (SEQ ID NO;
921), wherein;
X1 is Y, F, or D;
X2 is Y, L, S, or G;
X3 is K, T, R, or Y;
X4 is Y or W;
X5 is E, D, or I;
X6 is S, G, or Y;
X7 is F, Y, or T;
X8 is Y, F, or M;
X9 is G, T, or is not present;
X10 is M or is not present;
X11 is D; and
X12 is Y;
CDR-L1. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16 (SEQ ID NO;
922), wherein;
X1 is S, K, or R;
X2 is A or S;
X3 is S;
X4 is S or Q;
X5 is S or is not present;
X6 is L or is not present;
X7 is V or is not present;
X8 is H or is not present;
X9 is S or is not present;
X10 is S, N, or is not present;
X11 is S, V, or G;
X12 is I, N, or S;
X13 is S, N, T, or I;
X14 is Y or D;
X15 is M, V, L, or I; and
X16 is C, A, H, Y, or G;
CDR-L2. X1-X2-X3-X4-X5-X6-X7 (SEQ ID NO;
923), wherein;
X1 is D, Y, K, A, or H;
X2 is T, A, or V;
X3 is S or F;
X4 is K, N, or E;
X5 is L or R;
X6 is A, Y, or F; and
X7 is S or T;
andCDR-L3. X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO;
924), wherein;
X1 is Q, S, or H;
X2 is Q;
X3 is R, D, S, or G;
X4 is S, Y, or T;
X5 is S, G, or H;
X6 is Y, S, V, or A;
X7 is P or is not present;
X8 is W, Y, or L; and
X9 is T.
2 Assignments
0 Petitions
Accused Products
Abstract
Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
-
Citations
201 Claims
-
1. A binding protein comprising an antigen binding domain capable of binding human IL-17, said antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of:
-
CDR-H1. X1-X2-X3-X4-X5 (SEQ ID NO;
919), wherein;X1 is D or S; X2 is Y; X3 is E or G; X4 is I, M, V, or F; X5 is H; CDR-H2. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17 (SEQ ID NO;
920), wherein;X1 is V; X2 is T, I, or N; X3 is D, H, or W; X4 is P or is not present; X5 is E, G, or S; X6 is S, N, or D; X7 is G; X8 is G or T; X9 is T; X10 is L, A, T, or F; X11 is H or Y; X12 is N; X13 is P, Q, or S; X14 is K, A, or N; X15 is F or L; X16 is D, K, or R; and X17 is G, D, or S; CDR-H3. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 (SEQ ID NO;
921), wherein;X1 is Y, F, or D; X2 is Y, L, S, or G; X3 is K, T, R, or Y; X4 is Y or W; X5 is E, D, or I; X6 is S, G, or Y; X7 is F, Y, or T; X8 is Y, F, or M; X9 is G, T, or is not present; X10 is M or is not present; X11 is D; and X12 is Y; CDR-L1. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16 (SEQ ID NO;
922), wherein;X1 is S, K, or R; X2 is A or S; X3 is S; X4 is S or Q; X5 is S or is not present; X6 is L or is not present; X7 is V or is not present; X8 is H or is not present; X9 is S or is not present; X10 is S, N, or is not present; X11 is S, V, or G; X12 is I, N, or S; X13 is S, N, T, or I; X14 is Y or D; X15 is M, V, L, or I; and X16 is C, A, H, Y, or G; CDR-L2. X1-X2-X3-X4-X5-X6-X7 (SEQ ID NO;
923), wherein;X1 is D, Y, K, A, or H; X2 is T, A, or V; X3 is S or F; X4 is K, N, or E; X5 is L or R; X6 is A, Y, or F; and X7 is S or T; and CDR-L3. X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO;
924), wherein;X1 is Q, S, or H; X2 is Q; X3 is R, D, S, or G; X4 is S, Y, or T; X5 is S, G, or H; X6 is Y, S, V, or A; X7 is P or is not present; X8 is W, Y, or L; and X9 is T. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 32, 33, 34, 37, 38, 39, 41, 52, 53, 54, 55, 56, 57, 58, 63, 64, 65, 66, 67, 68, 69)
-
-
16-17. -17. (canceled)
-
29-31. -31. (canceled)
-
35-36. -36. (canceled)
-
40. (canceled)
-
42-51. -51. (canceled)
-
59-62. -62. (canceled)
-
70. A binding protein comprising an antigen binding domain capable of binding human IL-17, wherein said antigen binding domain comprises at least one CDR comprising an amino acid sequence selected from the group consisting of:
-
CDR-H1 selected from the group consisting of; X1-X2-X3-X4-X5 (SEQ ID NO;
925), wherein;X1 is N, A, D, or S; X2 is Y, F, or L; X3 is G, D, or A; X4 is M or I; and X5 is H, D, or S; a CDR-H1 of a variable heavy chain region (VH) of Table 21; a CDR-H1 of a VH of Table 23; a CDR-H1 of a VH of Table 24; and a CDR-H1 of a VH of Table 27; CDR-H2, selected from the group consisting of; X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17 (SEQ ID NO;
926), wherein;X1 is V, W, or G; X2 is I, T, M, or F; X3 is S, N, T, or D; X4 is Y or P; X5 is D, N, or I; X6 is G, S, L, or E; X7 is S or G; X8 is N, T, or E; X9 is K, T, or A; X10 is Y, G, N, or V; X11 is Y or V; X12 is A; X13 is D, P, or Q; X14 is S, K, or N; X15 is V or F; X16 is K, R, or Q; and X17 is G; a CDR-H2 of a VH of Table 21; a CDR-H2 of a VH of Table 23; a CDR-H2 of a VH of Table 24; and a CDR-H2 of a VH of Table 27; CDR-H3, selected from the group consisting of; X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17 (SEQ ID NO;
927), wherein;X1 is V, S, E, or I; X2 is G, S, P, or R; X3 is A, E, N, or P; X4 is S, D, or W; X5 is G, E, F, or L; X6 is D, G, or W; X7 is Y, I, N, or G; X8 is Y, T, G, or A; X9 is Y or I; X10 is S, G, or Y; X11 is Y, F, or T; X12 is G, T, or is not present; X13 is L, H, or is not present; X14 is H or is not present; X15 is F or is not present; X16 is D; and X17 is V, N, or Y; a CDR-H3 of a VH of Table 21; a CDR-H3 of a VH of Table 23; a CDR-H3 of a VH of Table 24; and a CDR-H1 of a VH of Table 27; CDR-L1, selected from the group consisting of; X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (SEQ ID NO;
928),wherein; X1 is S, R, or K; X2 is G or A; X3 is S or D; X4 is N, K, or Q; X5 is S or is not present; X6 is N or is not present; X7 is I, L, N, or D; X8 is G or I; X9 is S, N, G, or D; X10 is H, R, S, or D; X11 is S, Y, A, or D; X12 is V, A, L, or M; and X13 is N, C, or H; a CDR-L1 of a variable light chain region (VL) of Table 21; a CDR-L1 of a VL of Table 23; a CDR-L1 of a VL of Table 25; and a CDR-L1 of a VL of Table 27; CDR-L2, selected from the group consisting of; X1-X2-X3-X4-X5-X6-X7 (SEQ ID NO;
929), wherein;X1 is G, Q, Y, or E; X2 is I, D, or A; X3 is G, N, S, or T; X4 is Q, K, or T; X5 is R, S, or L; X6 is P, I, or V; and X7 is S or P; a CDR-L2 of a VL of Table 21; a CDR-L2 of a VL of Table 23; a CDR-L2 of a VL of Table 25; and a CDR-L2 of a VL of Table 27; and CDR-L3, selected from the group consisting of; X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11 (SEQ ID NO;
930), wherein;X1 is A, Q, H, or L; X2 is T or Q; X3 is W, S, or H; X4 is D or T; X5 is D or S; X6 is S, T, L, or F; X7 is L, T, or P; X8 is G, H, or Y; X9 is G, S, or T; X10 is Y or is not present; and X11 is V or is not present; a CDR-L3 of a VL of Table 21; a CDR-L3 of a VL of Table 23; a CDR-L3 of a VL of Table 25; and a CDR-L3 of a VL of Table 27. - View Dependent Claims (71, 103, 104, 106, 116, 117, 118, 122, 125, 126, 129, 130, 131, 132, 133)
-
-
72-102. -102. (canceled)
-
105. (canceled)
-
107-115. -115. (canceled)
-
119-121. -121. (canceled)
-
123-124. -124. (canceled)
-
127-128. -128. (canceled)
-
134-138. -138. (canceled)
-
139. A binding protein comprising first and second polypeptide chains, wherein said first polypeptide chain comprises a first polypeptide of formula VD1-(X1)n-VD2-C-(X2)n,
wherein VD1 is a first heavy chain variable domain; -
VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; and X2 is an Fc region; and wherein said second polypeptide chain comprises a second polypeptide of formula VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is 0 or 1; wherein the binding protein is capable of binding human IL-17 and TNF-α
;wherein said first heavy chain variable domain VD1 of said first polypeptide comprises an amino acid sequence of a variable heavy region (VH) of a parent anti-TNF-α
antibody or antigen binding portion thereof and said first light chain variable domain VD1 of said second polypeptide comprises an amino acid sequence of a variable light region (VL) of a parent anti-TNF-α
antibody or antigen binding portion thereof;wherein said second heavy chain variable domain VD2 of said first polypeptide comprises an amino acid sequence of a VH of a parent anti-IL-17 antibody or antigen binding portion thereof and said second light chain variable domain VD2 of said second polypeptide comprises an amino acid sequence of a VL of a parent anti-IL-17 antibody or antigen binding portion thereof; wherein said VD1 and VD2 heavy chain variable domains comprise an amino acid sequence of any of SEQ ID NOs;
562, 572, 577, 592, 627, 637, 647, 657, 667, 677, 687, 697, 707, 717, 727, 737, 747, 757, 762, 772, 782, 792, 802, 812, 822, 832, 842, 852, 862, 872, and 882; andwherein said VD1 and VD2 light chain variable domains comprise an amino acid sequence selected from the group consisting of SEQ ID NOs;
567, 582, 587, 597, 602, 607, 612, 617, 622, 632, 642, 652, 662, 672, 682, 692, 702, 712, 722, 732, 742, 752, 767, 777, 787, 797, 807, 817, 827, 847, 857, 867, and 877. - View Dependent Claims (140, 141, 152, 153, 154, 155, 159, 163, 164, 166, 177, 178, 181, 182, 185, 186)
-
-
142-150. -150. (canceled)
-
151. A binding protein capable of binding two antigens comprising four polypeptide chains, wherein a first and a third polypeptide chains comprise VD1-(X1)n-VD2-C-(X2)n, wherein
VD1 is a first heavy chain variable domain; -
VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; and X2 is an Fc region; and wherein a second and a fourth polypeptide chains comprise VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is 0 or 1; wherein the binding protein is capable of binding human IL-17 and TNF-α
;wherein the first heavy chain variable domain VD1 of the first and third polypeptide chains comprises an amino acid sequence of a variable heavy region (VH) of a parent anti-TNF-α
antibody or antigen binding portion thereof and the first light chain variable domain VD1 of the second and fourth polypeptide chains comprises an amino acid sequence of a variable light region (VL) of a parent anti-TNF-α
antibody or antigen binding portion thereof;wherein the second heavy chain variable domain VD2 of the first and third polypeptide chains comprises an amino acid sequence of a VH of a parent anti-IL-17 antibody or antigen binding portion thereof and the second light chain variable domain VD2 of the second and fourth polypeptide chains comprises an amino acid sequence of a VL of a parent anti-IL-17 antibody or antigen binding portion thereof; wherein the VD1 and VD2 heavy chain variable domains comprise an amino acid sequence of any of SEQ ID NOs;
562, 572, 577, 592, 627, 637, 647, 657, 667, 677, 687, 697, 707, 717, 727, 737, 747, 757, 762, 772, 782, 792, 802, 812, 822, 832, 842, 852, 862, 872, and 882; andwherein the VD1 and VD2 light chain variable domains comprise an amino acid sequence selected from the group consisting of SEQ ID NOs;
567, 582, 587, 597, 602, 607, 612, 617, 622, 632, 642, 652, 662, 672, 682, 692, 702, 712, 722, 732, 742, 752, 767, 777, 787, 797, 807, 817, 827, 847, 857, 867, and 877.
-
-
156-162. -162. (canceled)
-
160-162. -162. (canceled)
-
165. (canceled)
-
167-176. -176. (canceled)
-
179-180. -180. (canceled)
-
183-184. -184. (canceled)
-
187. (canceled)
-
188. A method for generating a DVD-Ig binding protein capable of binding two antigens comprising the steps of:
-
a) obtaining a first parent antibody or antigen binding portion thereof, capable of binding TNF-α
;b) obtaining a second parent antibody or antigen binding portion thereof, capable of binding human IL-17; c) constructing first and third polypeptide chains comprising VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first heavy chain variable domain obtained from said first parent antibody or antigen binding portion thereof; VD2 is a second heavy chain variable domain obtained from said second parent antibody or antigen binding portion thereof; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 is an Fc region; and n is 0 or 1; and d) constructing second and fourth polypeptide chains comprising VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first light chain variable domain obtained from said first parent antibody or antigen binding portion thereof; VD2 is a second light chain variable domain obtained from said second parent antibody or antigen binding thereof; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is 0 or 1; and e) expressing said first, second, third and fourth polypeptide chains;
such that a DVD-Ig binding protein capable of binding TNF-α and
human IL-17 is generated,wherein VD1 and VD2 heavy chain variable domains comprise an amino acid sequence selected from the group consisting of SEQ ID NOs;
of SEQ ID NOs;
562, 572, 577, 592, 627, 637, 647, 657, 667, 677, 687, 697, 707, 717, 727, 737, 747, 757, 762, 772, 782, 792, 802, 812, 822, 832, 842, 852, 862, 872, and 882; andwherein the VD1 and VD2 light chain variable domains comprise an amino acid sequence selected from the group consisting of SEQ ID NOs;
567, 582, 587, 597, 602, 607, 612, 617, 622, 632, 642, 652, 662, 672, 682, 692, 702, 712, 722, 732, 742, 752, 767, 777, 787, 797, 807, 817, 827, 847, 857, 867, and 877. - View Dependent Claims (191, 192, 195, 196, 197, 198, 199, 200)
-
-
189-190. -190. (canceled)
-
193-194. -194. (canceled)
-
201. (canceled)
Specification